Visibility of early gastric cancer in texture and color enhancement imaging

Seiichiro Abe¹ | Takayuki Yamazaki¹ | Izumi Tanimoto Hisada¹ | Mai Ego Makiguchi¹ | Shigetaka Yoshinaga¹ | Tomoya Sato² | Satoru Nonaka¹ | Haruhisa Suzuki¹ | Ichiro Oda¹,³ | Yutaka Saito¹

¹ Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan
² Department of Advanced Image Processing Technology, Olympus Medical Systems Corporation, Tokyo, Japan
³ Department of Internal Medicine, Kawasaki Rinko General Hospital, Kanagawa, Japan

Correspondence
Seiichiro Abe, MD, PhD, FASGE, FJGES, Endoscopy Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Email: seabe@ncc.go.jp

This study was registered with the University Hospital Medical Information Network (UMIN000043838).

Funding Information
Olympus Medical Systems, Grant/Award Number: C2020-036

Abstract
Objective: There are little data regarding the efficacy of texture and color enhancement imaging (TXI) for early gastric cancer (EGC) diagnosis. This study aimed to compare the color difference and visibility of EGC between white light imaging (WLI) and TXI.

Methods: This study included 20 EGCs of 18 patients undergoing endoscopic submucosal dissection. Still images of EGC in WLI, TXI mode 1 (with color enhancement), and TXI mode 2 (without color enhancement), which were consistent in distance, angle, and air insufflation, were constructed by computer simulation. The center of the lesion, eight equal peripheral points 5 mm outside the lesion, and eight inner points two-thirds of the distance from peripheral points to the EGC lesion center were annotated. Mean color differences (ΔE) of the area between peripheral and inner points per lesion in WLI, TXI mode 1, and TXI mode 2 were analyzed. In addition, four endoscopists independently scored the visibility of EGC images of TXI mode 1 and 2 compared with WLI.

Results: Clinicopathological characteristics were as follows: 0-IIa/0-IIb/0-IIc/0-IIa+IIc = 6/1/11/2, reddish/pale = 10/10, differentiated/undifferentiated = 18/2, median tumor size = 13.5 mm. Mean ΔE ± SD = WLI/TXI mode 1/TXI mode 2 = 10.3 ± 4.7, 15.5 ± 7.8, and 12.7 ± 6.1, respectively. Mean ΔE was significantly higher in TXI mode 1 than in WLI. Visibility (improved/no change/decreased) was 7/13/0 and 4/16/0 in TXI mode 1 and 2, respectively. The visibility was significantly more commonly improved in the macroscopic type 0-IIc or 0-IIb than in 0-IIa or Ila+IIC in TXI mode 1.

Conclusions: TXI could improve the visibility of EGC compared with WLI.

Keywords
early gastric cancer, image enhanced endoscopy, texture and color enhancement imaging, visibility
INTRODUCTION

Gastric cancer is the fifth most common malignant tumor and the third leading cause of cancer-related death worldwide.\(^1\) The prognosis of patients with gastric cancer depends on the cancer stage at diagnosis. Although patients with advanced gastric cancer have a poor prognosis, the 5-year disease-specific survival rate of patients with early gastric cancer (EGC) is greater than 90%.\(^2\) Thus, early detection is essential to improve the prognosis of gastric cancer.

Endoscopy has been recently accepted as a primary tool in population-based gastric cancer screening in countries with high gastric cancer incidence, such as Japan and Korea.\(^3,4\) However, sufficient training in countries with high gastric cancer incidence is presently under discussion.\(^12\)

METHODS

Study subject

This study was a post hoc analysis of a commissioned research at National Cancer Center Hospital, Tokyo, Japan. An expert endoscopist recognized by the Japanese Gastroenterological Endoscopy Society (SA), video-recorded preoperative endoscopies and stored raw video image data of EGC observation. This study included patients with EGCs for whom raw data were available, and who underwent endoscopic submucosal dissection (ESD) between July 26 and November 30, 2019. Availability of the endoscopy rooms equipped for raw data recording were limited, and the research allowed only one endoscopist to store the raw image data of EGC.

Patients without raw image data were excluded from analysis, either because preoperative EGD was performed by other endoscopists or because it was performed in endoscopy rooms where raw data could not be obtained. All EGCs were clinically diagnosed as gastric adenocarcinoma and met the criteria for ESD according to the Japanese Guidelines as follows: (a) differentiated-type mucosal cancer without ulceration, or (b) differentiated-type mucosal cancer ≤ 3 cm in diameter with ulceration, or (c) undifferentiated-type mucosal cancer ≤ 2 cm without ulceration.\(^14\) Gastric atrophy was graded according to the Kimura-Takemoto Classification.\(^15\) The study was conducted in accordance with the ethical principles included in the Declaration of Helsinki. We obtained approval from the institutional review board, and written informed consent was obtained from all patients. This study was registered with the University hospital Medical Information Network (UMIN000043838).

TXI

TXI is a novel image-enhanced endoscopy modality developed by Olympus Corporation (Tokyo, Japan).\(^13\) It enhances three aspects of white light endoscopy: (a) brightness in the dark areas, (b) texture such as subtle surface elevation or depression, and (c) color such as slight color changes in the images. It utilizes an image processing technology which is based on the Retinex theory.\(^16\) Applying its concept, an image is decomposed into two layers according to the working principles of the human visual system. One is a detail layer corresponding to the local contrast of brightness and color in the scene. The contrast enhancement of slight morphology or color change is achieved in the detail layer. The other is a base layer which represents the illumination component in the scene. It is difficult to adjust the brightness selectively in dark regions of an image by light source control, because light can only be applied across the entire image resulting in halation of the brighter areas. On the other hand, since the base layer corresponds to the illumination component, partial brightness control in the image can be achieved through processing techniques. The enhanced detail layer and the corrected base layer are recombined to produce one of the TXI outputs. In addition, the color tone of that output is highly enhanced, exaggerating the color difference in the images particularly between red and white hues.\(^17\) There are two settings for TXI: mode 1 with color enhancement, and mode 2 without color enhancement. Mode 2 produces images closer to WLI color tone (Figure 1).
**Image data collection**

The expert endoscopist performed the preoperative endoscopy of EGCs with a high definition gastroscope, GIF-H290Z and LUCERA ELITE system (Olympus Corporation), for patients sedated with intravenous propofol. Magnifying endoscopy with narrow-band imaging was also applied for the detailed assessment of the EGC margin. All preoperative endoscopies were video-recorded, and preprocessed raw image data (i.e., image sensor output) were obtained. The expert endoscopist selected one representative WLI from the recorded video which included an entire EGC lesion. The raw data of the representative image were then extracted, and the still images of EGC in WLI, TXI mode 1, and TXI mode 2 consistent in distance, angle, and air insufflation were constructed by computer simulation. All the simulations were conducted on a PC running Windows 10 professional 64-bit system utilizing Microsoft Visual Studio C++ 2012. Gastric ESD was performed according to the guidelines standard. The resected ESD specimens were fixed in 10% formalin before histopathological assessment. Histological mapping was performed after the specimens were serially sectioned at 2 mm intervals. Certified pathologists at our institution assessed the histological types, macroscopic appearance, tumor size, depth of invasion, presence of ulceration, lymphovascular invasion, and margin of all lesions according to the Japanese classification of gastric carcinoma.

**Annotation of lateral margin, peripheral, and inner points on EGC images**

The expert endoscopist defined the region of interest and delineated the margin of EGC on the WLI images based on magnifying endoscopy with NBI and matched histology mapping with markings at ESD. The endoscopist then manually annotated the center of the lesions, eight equal peripheral non-cancerous points at 10 × 10 pixels 5 mm outside the lesions (proximal, distal, anterior, posterior, and four midpoints between the two points), and eight inner cancerous points at 10 × 10 pixels two-thirds of the distance from peripheral points to the EGC lesion center (Figures 2a-2c). The eight equal peripheral points and eight inner points were similarly annotated on TXI mode 1 and mode 2 (Figures 2d and 2e).

**The color difference between peripheral and inner points on the EGC image**

The color in the endoscopic images was evaluated using the International Commission on Illumination L*a*b* (CIELAB) color space system. It is a three-dimensional space for presenting a color with axes of L* (from black to white; white is highest), a* (from green to red; red is highest), and b* (from blue to yellow; yellow is highest). The distance between two points in the CIELAB color space is proportional to the difference in color.
perception. Here, we assessed the perceived color difference of the area between peripheral points and inner points with the formula: $\Delta E = [(\Delta L^*)^2 + (\Delta a^*)^2 + (\Delta b^*)^2]^{1/2}$. The color difference analysis did not include the pairs between the peripheral and inner points if the inner points were annotated on the non-neoplastic area. We analyzed the color difference between peripheral points and inner points using the pairs where the data were available in all EGCs. Moreover, we performed a subanalysis of the mean color difference for EGCs in which the data were available in all eight pairs. Mean color differences of the area between peripheral and
inner points per lesion (mean ΔE) were analyzed in WLI, TXI mode 1, and TXI mode 2. ΔE was measured using MATLAB 2019b (The MathWorks, Inc., Massachusetts, USA).

Visibility assessment of EGC

Two expert endoscopists and two non-expert endoscopists evaluated the visibility of EGC. The former expert endoscopist who annotated the peripheral and inner points did not participate in this analysis. The four endoscopists independently reviewed the image data set consisting of 40 paired endoscopic images (20 WLI and TXI mode 1, and 20 WLI and TXI mode 2), which were randomly shown on a laptop monitor. They scored the visibility of EGC images of TXI mode 1 and 2 compared with WLI. Visibility of EGC was scored according to the following scale: +2 (improved visibility), +1 (somewhat improved visibility), 0 (visibility equivalent to that of WLI), −1 (somewhat decreased visibility), and −2 (decreased visibility). The improved visibility was defined as a total score of 5 or more, no change between −4 and 4 and decreased visibility as −5 or less, according to a previous study by Imagawa et al.20

Statistical analysis

Quantitative variables were shown as a mean with standard deviation and were analyzed using the Bonferroni test. A p value < 0.05 was considered statistically significant. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria).21

RESULTS

Among 129 EGCs in 120 patients undergoing ESD, a total of 20 EGCs in 18 patients (13 male and five female with median age [range] of 72 [39–83] years) were video-recorded and evaluated in this study. One hundred two patients without raw image data were excluded from analysis (Figure 3). The predominant macroscopic appearance was Type 0-IIc followed by Type 0-IIa, and the median tumor size (range) was 13.5 (2–32) mm. Ten lesions were reddish, and 10 were pale in color compared with background gastric mucosa. The majority of the lesions were characterized as differentiated-type mucosal EGC post H. pylori eradication. All EGC were resected en-bloc via ESD with adequate lateral and horizontal margin (Table 1).

The color difference was evaluated in all eight paired points in 13 EGCs. It could be analyzed in seven paired points in two EGCs, six paired points in one EGC, five paired points in one EGC, four paired points in two EGCs, and one paired points in one EGC, as the inner points where annotated on the non-neoplastic area were not evaluated. The color difference could be evaluated between the peripheral and inner points only at the distal side where the data were available in all 20 EGCs. The mean Δ ± SD of the distal side in WLI, TXI mode 1, and TXI mode 2 was 10.3 ± 4.7, 15.5 ± 7.8, and 12.7 ± 6.1, respectively. The mean ΔE was significantly higher in TXI mode 1 than in WLI (p = 0.04). There was no significant difference in the mean ΔE between TXI mode 1 and 2 (p = 0.54) and between WLI and TXI mode 2 (p = 0.61) (Table 2). Moreover, we also performed a subanalysis of the color difference in the 13 EGCs in which the data were available in all eight pairs. The mean Δ ± SD in WLI, TXI mode 1, and TXI mode 2 was 10.1 ± 3.0, 13.5 ± 3.4, and 11.3 ± 2.6, respectively. The mean ΔE was significantly higher in TXI mode 1 than in WLI (p = 0.04). There was no

| TABLE 1 | Patient and lesion characteristics |
|---|---|
| Gender, male/female, n | 13/5 |
| Median age (range), year | 72 (39–82) |
| Gastric atrophy* (C-1~2/C-3, O-1/O-2~3), n | 4/4/10 |
| H. pylori infection Positive/negative/eradicated, n | 2/4/12 |
| Lesion location, upper/middle/lower, n | 10/7/3 |
| Median tumor size (range), mm | 13.5 (2–32) |
| Macroscopic type 0-IIa/0-IIb/0-IIc/0-IIa+b-IIc, n | 6/1/1/2 |
| Color (reddish/pale), n | 10/10 |
| Histological type Differentiated/Undifferentiated, n | 18/2 |
| Depth of invasion, M/SM1, n | 19/1 |

Abbreviations: M, mucosa; SM1, superficial submucosa < 500µm. *Graded by Kimura Takemoto Classification.
significant difference in the mean ΔE between TXI mode 1 and 2 (p = 0.24) and between WLI and TXI mode 2 (p = 0.86).

The visibility scores rated by the four endoscopists are shown in Table 3. The mean total visibility scores were 3.4 ± 2.0 and 3.0 ± 1.9 in TXI mode 1 and 2, respectively. Visibility was improved in 35% (7/20) and 20% (4/20), and unchanged in 65% (13/20) and 80% (16/20) in TXI mode 1 and 2 compared with WLI, respectively. None of the lesions were scored as decreased visibility. The mean visibility scores between non-expert and expert endoscopists were 1.6 versus 1.9 and 1.5 versus 1.5 in TXI mode 1 and TXI mode 2, respectively. The visibility was significantly more commonly improved in the macroscopic type 0-IIc or 0-IIb than in 0-IIa or IIa + IIIc in TXI mode 1 (p = 0.04) (Table 4, Figure 4). There was no lesion characteristic associated with improved visibility in TXI mode 2 (Table 5).

### TABLE 4  
Lesion characteristics with and without improved visibility in TXI mode 1

|                          | Improved n = 7 | No change n = 13 | p value |
|--------------------------|----------------|------------------|---------|
| Location                 |                |                  |         |
| U/ML, % (n)              | 0/100          | 38.5/61.5        | 0.11    |
|                          | (0/7)          | (5/8)            |         |
| Color                    |                |                  |         |
| Reddish/pale, % (n)      | 28.6/71.4      | 61.5/38.5        | 0.35    |
|                          | (2/5)          | (8/5)            |         |
| Macroscopic type         |                |                  |         |
| 0-IIc,0-IIb/0-IIa,IIa+IIc, % (n) | 100/0       | 38.5/61.5        | 0.01    |
|                          | (7/0)          | (5/8)            |         |
| Histology                |                |                  |         |
| D-type/UD-type, % (n)    | 85.7/14.3      | 92.3/7.7         | 1.0     |
|                          | (6/1)          | (12/1)           |         |
| Size                     |                |                  |         |
| ≤10mm/>11mm, % (n)       | 57.1/42.9      | 46.2/53.8        | 1.0     |
|                          | (4/3)          | (6/7)            |         |
| Depth of invasion        |                |                  |         |
| M/SM, % (n)              | 100/0          | 92.3/7.7         | 1.0     |
|                          | (7/0)          | (12/1)           |         |
| H.pylori infection       |                |                  |         |
| Positive/Eradicated/Negative, % (n) | 0/71.4/28.6 | 15.4/69.2/15.4  | 0.52    |
|                          | (0/5/2)        | (2/9/2)          |         |

*Positive versus eradicated, negative.

Abbreviations: D-type, differentiated type; M/SM, mucosa/submucosa; UD-type, undifferentiated type; U/ML, upper third/middle third/lower third.
FIGURE 4  A representative case of EGC with improved visibility. (a) WLI showed a slightly pale lesion in the anterior wall of the antrum. The mean $\Delta E$ was 4.34. (b) TXI mode 1 demonstrated enhancement of the depression and pale color with a mean $\Delta E$ of 7.18. The visibility was scored as improved, with a total visibility score of 6. (c) TXI mode 2 demonstrated enhancement of the depression with a mean $\Delta E$ of 6.04. The visibility was scored as improved, with a total visibility score of 7.

TABLE 5  Lesion characteristics with and without improved visibility in TXI mode 2

| Characteristics          | Improved $n = 4$ | No change $n = 16$ | $p$ value |
|--------------------------|-----------------|-------------------|-----------|
| Location                 |                 |                   |           |
| U/ML, % ($n$)            | 0/100           | 18.7/81.3         | 1.0       |
|                          | (0/4)           | (3/13)            |           |
| Color                    |                 |                   |           |
| Reddish/pale, % ($n$)    | 25/75           | 56.2/43.8         | 0.58      |
|                          | (1/3)           | (9/7)             |           |
| Macroscopic type         |                 |                   |           |
| 0-IIc,0-IIb/0-IIa,IIa+IIc, % ($n$) | 100/0 | 50/50   | 0.12      |
|                          | (4/0)           | (8/8)             |           |
| Histology                |                 |                   |           |
| D-type/UD-type, % ($n$)  | 100/0           | 87.5/12.5         | 1.0       |
|                          | (4/0)           | (14/2)            |           |
| Size                     |                 |                   |           |
| ≤10mm/>11mm, % ($n$)     | 50/50           | 50/50             | 1.0       |
|                          | (2/2)           | (8/8)             |           |
| Depth of invasion        |                 |                   |           |
| M/SM, % ($n$)            | 100/0           | 93.8/6.2          | 1.0       |
|                          | (4/0)           | (15/1)            |           |
| H. pylori infection      |                 |                   |           |
| Positive/Eradicated/Negative, % ($n$) | 0/75/25  | 12.5/68.8/18.7  | 1.0*      |
|                          | (0/3/1)         | (2/11/3)          |           |

*Positive versus eradicated, negative.

Abbreviations: D-type, differentiated type; M/SM, mucosa/submucosa; UD-type: undifferentiated type; U/M/L, upper third/middle third/lower third.
subtle color and morphological differences on gastric mucosal compared with conventional WLI is plausible. This study indicated that TXI could improve endoscopic visibility of EGC, potentially increasing EGC detection during screening EGD. Notably, the visibility was significantly more commonly improved in the macroscopic type 0-IIc or 0-IIb than 0-IIa or 0-IIa+IIc. This is worthwhile noting when considering the application of TXI in daily clinical practice because 0-IIc is the most major macroscopic type of EGC.

To the best of our knowledge, there was only one previous study that reported the visibility of EGC in TXI. Ishikawa et al recently investigated the color difference between non-neoplastic and neoplastic areas of 12 gastric neoplasms in WLI and TXI. The color differences ± SD in WLI, TXI mode 1, and TXI mode 2 were 8.000 ± 4.263, 18.728 ± 16.046, and 10.246 ± 8.379, respectively. The color difference was significantly higher in TXI mode 1 than WLI and TXI mode 2. In addition, the visibility of gastric neoplastic lesion (gastric adenocarcinoma and adenoma) evaluated by six endoscopists was better in TXI mode 1 compared with WLI.23 The reason for inconsistent results could be explained by the image data. They manually annotated a couple of inner and peripheral points for each image. It would have been very challenging during endoscopy to capture still images of EGC in WLI, TXI mode 1, and TXI mode 2 at exactly the same distance, angle, and air insufflation. These factors could influence the results of their study. In our study, we constructed still images of TXI mode 1 and TXI mode 2 from WLI images consistent in distance, angle, and air insufflation, using computer simulation. The color difference was evaluated in only one pair where the data were available in all 20 EGCs, as done by Ishikawa et al. However, the data of our study were reinforced by the subanalysis using 13 EGCs in which the mean color difference could be analyzed in all eight pairs. Because the annotation can greatly influence the data interpretation of color difference between non-neoplastic and neoplastic areas, we believe our study demonstrated more objective data analysis of color difference than the former study.

Other image-enhanced endoscopies could improve visibility and EGC detection rate during screening EGD.24 Among them, blue light imaging made from the combination of strong laser light with a 410 nm wavelength and weak laser light with a 450 nm wavelength, was reported to have a higher real-time EGC detection rate than WLI.25 Linked color imaging (LCI) is another color enhancement technology that provides enhanced color differences in mucosal color, allowing better lesion recognition with sufficient brightness compared with BLI. It is a similar image enhanced technology to TXI, and a randomized controlled trial showed LCI is more effective than WLI for detecting neoplastic lesions in the pharynx, esophagus, and stomach (4.8% vs. 8.0%, $p = 0.011$).26 However, there was no statistically significant difference in the gastric neoplastic lesion detection rates (3.3% vs. 5.5%), perhaps owing to insufficient sample size. The primary endpoint included pharyngeal and esophageal neoplastic lesions as well as gastric neoplastic lesion. Another randomized controlled trial by Yoshida et al compared the EGC detection rate between WLI and second-generation NBI and concluded that second-generation NBI did not increase EGC detection compared with WLI.27 The Japanese Guidelines for Endoscopic Diagnosis of Early Gastric Cancer stated that the utility of image-enhanced endoscopy for detecting EGC remains unclear.12 The results of this study were not relevant to gastric cancer detection. The skill and experience of endoscopist are also associated with the detection. The potential of TXI, consisting of the combination of texture and color enhancement, should be further evaluated. Large clinical trials are warranted to investigate the performance of TXI during real-time EGC screening.

There were some limitations in this study. Firstly, the sample size was small, and selection bias could have influenced the results. H. pylori infection status may affect the visibility of TXI. However, we could not sufficiently evaluate it. Secondly, this study utilized image-based analysis, and TXI was not performed in real clinical setting but constructed with computer simulation. Conversely, a more objective image analysis was achieved, as TXI and WLI images uniform in distance, angle, and air insufflation were used, rather than images taken from real clinical setting where consistent images across the modality would not be possible. Thirdly, the endoscopists were not blinded whether an image was WLI or TXI. Finally, this study did not analyze the visibility of non-cancerous lesions. Further investigation is required in clinical practice.

In conclusion, TXI could improve the visibility of EGC compared with WLI.

ACKNOWLEDGMENT

We would like to thank Dr. Shih Yea Sylvia Wu (Endoscopy Unit, Hutt Hospital, Wellington, New Zealand) for her kind support of this article.

CONFLICT OF INTEREST

The author Seiichiro Abe was supported by a research grant from Olympus Medical Systems (C2020-036). The authors Seiichiro Abe and Yutaka Saito received honoraria for lectures from Olympus Medical Systems. The author Seiichiro Abe is an associate editor of DEN Open.

FUNDING INFORMATION

The author Seiichiro Abe was supported by a research grant from Olympus Medical Systems (C2020-036).

ORCID

Seiichiro Abe 🏛️ https://orcid.org/0000-0002-2736-6921
REFERENCES

1. Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2018; 144: 1941–53.

2. Katai H, Ishikawa T, Akazawa K, et al. Five-year survival analysis of surgically resected gastric cancer cases in Japan: A retrospective analysis of more than 100,000 patients from the nationwide registry of the Japanese Gastric Cancer Association (2001-2007). Gastric Cancer 2017; 21: 144–54.

3. Hamashima C. Update version of the Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol 2018; 48: 673–83.

4. Jun JK, Choi KS, Lee HY, et al. Effectiveness of the Korean national cancer screening program in reducing gastric cancer mortality. Gastroenterology 2017; 152: 1319–28.

5. Amin A, Gilmour H, Graham L, Paterson-Brown S, Terrace J, Crofts TJ. Gastric adenocarcinoma missed at endoscopy. J R Coll Surg Edinb 2002; 47: 681–4.

6. Hosokawa O, Tsuda S, Kidani E, et al. Diagnosis of gastric cancer up to three years after negative upper gastrointestinal endoscopy. Endoscopy 1998; 30: 669–74.

7. Menon S, Trudgill N. How commonly is upper gastrointestinal cancer missed at endoscopy? A meta-analysis. Endosc Int Open 2014; 2: E46–50.

8. Raftopoulos SC, Segarajasingam DS, Burke V, Ee HC, Yusoff IF. A cohort study of missed and new cancers after esophagogastroduodenoscopy. Am J Gastroenterol 2010; 105: 1292–7.

9. Voutilainen ME, Juhola MT. Evaluation of the diagnostic accuracy of gastroscopy to detect gastric tumours: Clinicopathological features and prognosis of patients with gastric cancer missed on endoscopy. Eur J Gastroenterol Hepatol 2005; 17: 1345–9.

10. Vradelis S, Maynard N, Warren BF, Keshav S, Travis SP. Quality control in upper gastrointestinal endoscopy: Detection rates of gastric cancer in Oxford 2005–2008. Postgrad Med J 2011; 87: 335–9.

11. Yalamarthi S, Witherspoon P, McCole D, Auld CD. Missed diagnoses in patients with upper gastrointestinal cancers. Endoscopy 2004; 36: 874–9.

12. Yao K, Uedo N, Kamada T, et al. Guidelines for endoscopic diagnosis of early gastric cancer. Dig Endosc 2020; 32: 663–698.

13. Sato T. TXI: Texture and color enhancement imaging for endoscopic image enhancement. J Healthc Eng 2021; 2021: 5518948.

14. Ono H, Yao K, Fujishiro M, et al. Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer. Dig Endosc 2016; 28: 3–15.

15. Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1969; 1: 87–97.

16. Meylan L, Süssstrunk S. High dynamic range image rendering with a Retinex-based adaptive filter. IEEE Trans Image Process 2006; 15: 2820–30.

17. Kuehni RG. Color-tolerance data and the tentative CIE 1976 L*a*b formula. J Opt Soc Am 1976; 66: 497–500.

18. Nagahama T, Yao K, Uedo N, et al. Delineation of the extent of early gastric cancer by magnifying narrow-band imaging and chromoendoscopy; A multicenter randomized controlled trial. Endoscopy 2018; 50: 566–76.

19. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011; 14: 101–12.

20. Imagawa H, Oka S, Tanaka S, et al. Improved visibility of lesions of the small intestine via capsule endoscopy with computed virtual chromoendoscopy. Gastrointest Endosc 2011; 73: 299–306.

21. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013; 48: 452–8.

22. Tajihi H, Dinis-Ribeiro M. How I inspect the stomach. Gastrointest Endosc 2019; 89: 1106–8.

23. Ishikawa T, Matsumura T, Okimoto K, et al. Efficacy of Texture and Color Enhancement Imaging in visualizing gastric mucosal atrophy and gastric neoplasms. Sci Rep 2021; 11: 6910.

24. Yoshifuku Y, Sanomura Y, Oka S, et al. Evaluation of the visibility of early gastric cancer using linked color imaging and blue laser imaging. BMC Gastroenterol 2017; 17: 150.

25. Dohi O, Yagi N, Naito Y, et al. Blue laser imaging-bright improves the real-time detection rate of early gastric cancer: A randomized controlled study. Gastrointest Endosc 2019; 89: 47–57.

26. Ono S, Kawada K, Dohi O, et al. Linked color imaging focused on neoplasm detection in the upper gastrointestinal tract: A randomized trial. Ann Intern Med 2021; 174: 18–24.

27. Yoshida N, Doyama H, Yano T, et al. Early gastric cancer detection in high-risk patients: A multicentre randomised controlled trial on the effect of second-generation narrow band imaging. Gut 2021; 70: 67–75.